Fintel on MSN1d
JMP Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Market Outperform RecommendationFintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Market Outperform recommendation. Analyst Price Forecast Suggests 219.11% ...
Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...
JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) passed above its 50-day moving average during trading on Wednesday .The stock has a 50-day moving average of $8.87 and ...
Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...
A series of injectable and oral treatments that require chronic dosing are already available, while others are nearing the market, including KalVista Pharma's recently filed oral plasma kallikrein ...
After hours: January 29 at 5:06:57 p.m. EST ...
Insider Buying and Selling at Microsoft In other news, EVP Christopher David Young sold 7,200 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback